$31.00
Manufacturer: Spain
Treatment of bronchospasm in patients with chronic obstructive pulmonary disease (COPD) who require regular use of ipratropium bromide and salbutamol.
Description
Ipratropium-Inteli Storage
active substance: ipratropium bromide;
1 dose contains 21 μg of ipratropium bromide monohydrate (equivalent to 20 μg of ipratropium bromide anhydrous);
Excipients: anhydrous citric acid, purified water, 1,1,1,2-tetrafluoroethane (HFA-134a), absolute ethanol.
Ipratropium-Inteli Dosage form
Inhalation under pressure, solution.
Basic physical and chemical properties: transparent and colorless solution.
Ipratropium-Inteli Pharmacotherapeutic group
Means for the treatment of obstructive airways diseases. Other antiasthmatic drugs used by inhalation. Anticholinergic drugs. Ipratropium bromide.
ATX code R03B B01.
Pharmacological properties
Pharmacodynamics
Ipratropium bromide is a Quaternary ammonium salt that blocks muscarinic cholinergic receptors and reduces the formation of cyclic guanosine monophosphate (cGMP), preventing the interaction of acetylcholine with muscarinic receptors of bronchial smooth muscle. Elevated levels of cGMP cause degranulation of mast cells and contraction of bronchial smooth muscle.
Ipratropium bromide is a non-selective muscarinic antagonist and does not enter the bloodstream, which prevents the development of systemic side effects. Ipratropium bromide is a derivative of atropine, but also a Quaternary amine, so it does not cross the blood-brain barrier, which prevents the development of side effects from the central nervous system (anticholinergic syndrome).
When inhalers have been used in patients with bronchospasm associated with chronic obstructive pulmonary disease, there has been a significant improvement in lung function (forced expiratory rate of FEV1 increases by 15% or more).
No adverse effect of ipratropium bromide on mucus secretion in the respiratory tract, mucociliary clearance or gas exchange was detected.
Indication
Supportive care for reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic bronchial asthma.
Contraindication
Hypersensitivity to atropine or its derivatives (eg tiotropium), ipratropium bromide, or to any component of the drug.
Special security measures
Caution should be exercised when using inhalations and do not allow the solution to get into the eyes.
Recent Reviews